title: The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome.
abstract: Abstract The use of dual antiplatelet therapy has led to a substantial reduction in ischemic events post-acute coronary syndrome (ACS). Despite this, recurrent event rates remain high. Recent research has combined antiplatelet with anticoagulant therapy to reduce recurrent event rates further. Compared with standard medical therapy, rivaroxaban demonstrated improved efficacy outcomes and significantly reduced mortality after an ACS. Although clear benefits of novel oral anticoagulants post-ACS have been proven, concerns regarding bleeding are still a barrier to widespread use. This review explores key trials of dual antiplatelet therapy and examines the latest research in anticoagulation aiming to optimize clinical outcomes post-ACS.
authors.affiliation: Royal Brisbane and Women's Hospital and the University of Queensland , Queensland , Australia.
authors.forename: A C
authors.initials: AC
authors.lastname: Camuglia
authors.forename: K E
authors.initials: KE
authors.lastname: Waddell-Smith
authors.forename: C J
authors.initials: CJ
authors.lastname: Hammett
authors.forename: P E
authors.initials: PE
authors.lastname: Aylward
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000517:prevention & control*; D000925:Anticoagulants / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000069552:Rivaroxaban; D055502:Secondary Prevention; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000069552:Rivaroxaban
keywords: ACS; Acute coronary syndrome; Anticoagulants; Antiplatelets; Rivaroxaban